

Cleansing Notice under section 708A(5)(e) of the Corporations Act

This notice is given by **Microba Life Sciences Limited** (ASX: MAP) ("**Microba**" or "the **Company**") under section 708A(5)(e) of the *Corporations Act 2001 (Cth)* (**Corporations Act**).

On 12 June 2026, Microba announced a capital raise to the ASX consisting of:

- **Placement** - a placement to raise \$5.0 million before costs by the issue of 100,004,240 ordinary shares (**New Shares**) at \$0.05 per New Share, plus 100,004,240 free-attaching options (**New Options**) on the basis of one (1) New Option for every one (1) New Share subscribed for under the placement (**Placement**).

The Placement will complete in two tranches, with 91,344,455 New Shares being issued under tranche 1 of the Placement (**Tranche 1 Placement Shares**) and 8,659,785 New Shares being issued under tranche 2 of the Placement (**Tranche 2 Placement Shares**).

All New Options for both tranches of the Placement will be issued at the same time as the Tranche 2 Placement Shares.

- **Share Purchase Plan** - a share purchase plan to eligible Microba shareholders to raise up to a further \$1.0 million before costs by the issue of approximately 20,000,000 New Shares at \$0.05 per New Share, plus approximately 20,000,000 free-attaching New Options on the basis of one (1) New Option for every one (1) New Share subscribed for under the share purchase plan (**SPP Offer**).

The Tranche 1 Placement Shares were issued on 18 June 2026 and an Appendix 2A has been lodged with the ASX for quotation of those Tranche 1 Placement Shares.

Details of the Placement

Details of the issue of Tranche 1 Placement Shares is provided below:

Class of Securities:	Fully paid ordinary shares
ASX Code of the securities:	ASX : MAP
Date of the issue:	18 June 2026
Total number of Tranche 1 Placement Shares:	91,344,455

In accordance with section 708A(6) of the Corporations Act, Microba gives notice that:

- the Tranche 1 Placement Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- this notice is being given under section 708A(5)(e) of the Corporations Act;
- as of the date of this notice, the Company has complied with:
 - the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - sections 674 and 674A of the Corporations Act; and
- as of the date of this notice, there is no "excluded information" as defined in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by the Company.

This announcement has been authorised for release by the Board of Directors.



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit ir.microba.com/welcome

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621

For further information, please contact:

Dr Luke Reid

Chief Executive Officer
luke.reid@microba.com

Investor / Media Relations

investor@microba.com
<https://ir.microba.com/welcome>

About Microba Life Sciences Limited

Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com

For personal use



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit ir.microba.com/welcome

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621

